ESR1 and breast carcinoma: Thirty-one percent of the women with ER-positive/HER2-negative breast cancer had a decrease in Ki-67 of at least 10%, and 50% of women with triple-negative breast cancer (TNBC) had a decrease in Ki-67 of 10% or greater with VPA treatment.